Liquidia Technologies is a biopharmaceutical company that develops inhaled and intravenous therapies for patients with pulmonary arterial hypertension and related pulmonary vascular diseases. The company's primary revenue comes from direct sales of YUTREPIA, its proprietary inhaled treprostinil powder formulation that uses the company's patented PRINT particle-engineering technology, and from profit-sharing on a generic injectable treprostinil commercialized through a partnership with Sandoz; the company also has an investigational pipeline candidate and has licensed its PRINT technology to other pharmaceutical companies. Liquidia targets pulmonary disease specialists and cardiologists through a specialized commercial field force, competing against other inhaled and oral prostacyclin therapies and drugs acting on alternative disease pathways.